Publication Name	World Journal of Clinical Cases
Manuscript ID	70007
Country	China

Received	2021-07-26 07:29
Peer-Review Started	2021-07-26 07:31
To Make the First Decision
Return for Revision	2021-10-22 02:11
Revised	2021-10-25 02:23
Second Decision	2022-01-28 03:11
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2022-01-29 07:04
Articles in Press	2022-01-29 07:04
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2022-02-27 12:39
Publish the Manuscript Online	2022-03-11 00:39

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Immunology
Manuscript Type	Case Report
Article Title	Metastatic urothelial carcinoma harboring ERBB2/3 mutations dramatically respond to chemotherapy plus anti-PD-1 antibody: A case report
Manuscript Source	Unsolicited Manuscript
All Author List	Fei-Fei Yan, Qi Jiang, Bin Ru, Xiao-Jie Fei, Jian Ruan and Xiao-Chen Zhang
ORCID	Author(s) ORCID Number Fei-Fei Yan http://orcid.org/0000-0001-5003-096X Qi Jiang http://orcid.org/0000-0002-5307-3129 Bin Ru http://orcid.org/0000-0003-0628-3243 Xiao-Jie Fei http://orcid.org/0000-0002-8914-0573 Jian Ruan http://orcid.org/0000-0003-1354-4720 Xiao-Chen Zhang http://orcid.org/0000-0002-7014-868X
Funding Agency and Grant Number	Funding Agency Grant Number Zhejiang Medical Association 2018ZYC-A18
Corresponding Author	Xiao-Chen Zhang, Doctor, MD, Associate Chief Physician, Chief Physician, Doctor, Doctor, Department of Medical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Hangzhou 310000, Zhejiang Province, China. zhangxiaochen@zju.edu.cn
Key Words	Urothelial carcinoma; Bladder cancer; ERBB; Programmed death; Sindilimab; Case report
Core Tip	Immune checkpoint inhibitors (ICIs) have substantially changed the clinical management of metastatic urothelial carcinoma (mUC); however, the response rate to monotherapy remains low. Previous studies have suggested that ERBB2/3 mutations are associated with the efficacy of ICIs in gallbladder carcinoma. The present case of mUC harboring ERBB2/3 mutations, negative programmed death (PD)-ligand 1 expression, and low tumor mutation burden showed durable response to anti-PD-1 antibodies combined with paclitaxel as second-line treatment. Further studies are required to investigate this finding.
Publish Date	2022-03-11 00:39
Citation	Yan FF, Jiang Q, Ru B, Fei XJ, Ruan J, Zhang XC. Metastatic urothelial carcinoma harboring ERBB2/3 mutations dramatically respond to chemotherapy plus anti-PD-1 antibody: a case report. World J Clin Cases 2022; 10(8): 2497-2503
URL	https://www.wjgnet.com/2307-8960/full/v10/i8/2497.htm
DOI	https://dx.doi.org/10.12998/wjcc.v10.i8.2497

Full Article (PDF)	WJCC-10-2497.pdf
Full Article (Word)	WJCC-10-2497.docx
CARE Checklist–2016	70007-CARE-Checklist–2016-revision.jpg
Manuscript File	70007_Auto_Edited.docx
Answering Reviewers	70007-Answering reviewers.pdf
Audio Core Tip	70007-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	70007-Conflict-of-interest statement.pdf
Copyright License Agreement	70007-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	70007-Grant application form(s).pdf
Signed Consent for Treatment Form(s) or Document(s)	70007-Informed consent statement.pdf
Non-Native Speakers of English Editing Certificate	70007-Language certificate.pdf
Peer-review Report	70007-Peer-review(s).pdf
Scientific Editor Work List	70007-Bing-Ma YJ-2.png
Scientific Editor Work List	70007-Scientific editor work list.pdf
CrossCheck Report	70007-CrossCheck Report.pdf